Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Lexicon Pharmaceuticals, Inc. (LXRX:NASDAQ), powered by AI.
Lexicon Pharmaceuticals, Inc. is currently trading at $1.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Lexicon Pharmaceuticals, Inc. on Alpha Lenz.
View Lexicon Pharmaceuticals, Inc.'s valuation metrics on Alpha Lenz.
“Lexicon Pharmaceuticals, Inc.'s ROE is -39.7%. Explore profitability and growth together.”
Ask for details →Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Leveraging advanced gene knockout technology, the company aims to identify and develop therapies from its extensive portfolio of drug targets. Its primary mission is to create innovative pharmaceutical products that offer substantial benefits over existing treatment options, particularly in areas of unmet medical needs. Notably impacting the health and biotechnology sectors, Lexicon is involved in pivotal research for conditions such as diabetes, carcinoid syndrome, and heart diseases. With a dedication to improving patient outcomes, the company collaborates extensively within the scientific community and regulatory bodies to advance its clinical programs from the laboratory through to regulatory approval. In doing so, Lexicon Pharmaceuticals plays a significant role in the biomedical market, contributing to the ongoing development and accessibility of novel medical therapies.
“Lexicon Pharmaceuticals, Inc.'s ROE is -39.7%. Explore profitability and growth together.”
Ask for details →Lexicon Pharmaceuticals, Inc. (ticker: LXRX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 103 employees.
The current price is $1.95 with a P/E ratio of -x and P/B of -x.
ROE is -39.72% and operating margin is -98.21%. Annual revenue is $50M.